E-LIB Suche - Ergebnisse für: Chapman, Richard H.

1

Patient-Informed Value Elements in Cost-Effectiveness Analy..:

Slejko, Julia F. ; Mattingly II, T. Joseph ; Wilson, Alexandra...
Value in Health. , 2024

Link: https://doi.org/10.1016/..

2

Cost-Effectiveness of Nadofaragene Firadenovec and Pembroli..:

Joshi, Mrinmayee ; Atlas, Steven J. ; Beinfeld, Molly...
Value in Health. 26 (2023) 6 - p. 823-832 , 2023

Link: https://doi.org/10.1016/..

3

Preferences for Treatments for Major Depressive Disorder: F..:

dosReis, Susan ; Bozzi, Laura M. ; Butler, Beverly...
The Patient - Patient-Centered Outcomes Research. 16 (2022) 1 - p. 57-66 , 2022

Link: https://doi.org/10.1007/..

4

Developing a Framework for the Health Technology Assessment..:

Gaultney, Jennifer G. ; Bouvy, Jacoline C. ; Chapman, Richard H....
Applied Health Economics and Health Policy. 19 (2021) 5 - p. 625-634 , 2021

Link: https://doi.org/10.1007/..

5

Does Cost-Effectiveness Analysis Overvalue Potential Cures?..:

Chapman, Richard H. ; Kumar, Varun M. ; Whittington, Melanie D..
Value in Health. 24 (2021) 6 - p. 839-845 , 2021

Link: https://doi.org/10.1016/..

6

Cost effectiveness of nusinersen for patients with infantil..:

Thokala, Praveen ; Stevenson, Matt ; Kumar, Varun M....
Cost Effectiveness and Resource Allocation. 18 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

7

Modeling Medicaid and Medicare Savings from Reduced Poverty..:

Counts, Nathaniel Z. ; Gionfriddo, Paul ; Chapman, Richard H.
Applied Health Economics and Health Policy. 18 (2020) 5 - p. 601-604 , 2020

Link: https://doi.org/10.1007/..

8

Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cy..:

Wherry, Kael ; Williamson, Ian ; Chapman, Richard H..
Value in Health. 23 (2020) 10 - p. 1332-1339 , 2020

Link: https://doi.org/10.1016/..

9

Achieving Appropriate Model Transparency: Challenges and Po..:

Carlson, Josh J. ; Walton, Surrey M. ; Basu, Anirban...
PharmacoEconomics. 37 (2019) 11 - p. 1321-1327 , 2019

Link: https://doi.org/10.1007/..

10

Author Reply:

Zimmermann, Marita ; Lubinga, Solomon J. ; Banken, Reiner...
Value in Health. 22 (2019) 8 - p. 972-973 , 2019

Link: https://doi.org/10.1016/..

11

Cost Utility of Voretigene Neparvovec for Biallelic RPE65-M..:

Zimmermann, Marita ; Lubinga, Solomon J. ; Banken, Reiner...
Value in Health. 22 (2019) 2 - p. 161-167 , 2019

Link: https://doi.org/10.1016/..

12

Current Value Frameworks—What's New?:

Willke, Richard J. ; Chapman, Richard H. ; Seidman, Joshua J...
Value in Health. 22 (2019) 6 - p. S7-S11 , 2019

Link: https://doi.org/10.1016/..

13

Impact of Abuse Deterrent Formulations of Opioids in Patien..:

Kumar, Varun M. ; Agboola, Foluso ; Synnott, Patricia G....
Value in Health. 22 (2019) 4 - p. 416-422 , 2019

Link: https://doi.org/10.1016/..

14

United States Valuation of EQ-5D-5L Health States Using an ..:

Pickard, A. Simon ; Law, Ernest H. ; Jiang, Ruixuan...
Value in Health. 22 (2019) 8 - p. 931-941 , 2019

Link: https://doi.org/10.1016/..

15

New Cost-Effectiveness Methods to Determine Value-Based Pri..:

Pearson, Steven D. ; Ollendorf, Daniel A. ; Chapman, Richard H.
Value in Health. 22 (2019) 6 - p. 656-660 , 2019

Link: https://doi.org/10.1016/..